Apimeds Pharmaceuticals US I (APUS) Institutional Holdings & 13F Data (Q2 2026)

On August 19, 2026, Apimeds Pharmaceuticals US (APUS) signed an agreement with Korea's FreeT Inc. under which FreeT irrevocably handed over all of its rights tied to Apitox, a bee-venom-based drug candidate. The package covers 100% of the Apitox rights for the Korean medicine clinic market in South Korea, a 25% royalty on proceeds from developing or commercializing Apitox in the U.S., a 25% cut of net proceeds from overseas licensing deals, and quarterly briefings on both the clinical program and international transactions. Two caveats worth knowing: the deal leaves out the underlying intellectual property ownership of Apitox, along with any global rights FreeT never held, and while the company says the transferred rights arrive clean — no leftover claims from earlier side arrangements — it takes on none of FreeT's pre-existing debts.

No AI summary for this filing type

Apimeds Pharmaceuticals US (APUS) has delayed its previously announced 1-for-10 reverse stock split from March 2026 to July 2026. The split will combine every ten shares of common stock into one share and is expected to become effective on July 24, 2026. The company had originally planned to file the necessary charter amendment in March but did not do so; it now expects to file on July 23, with the split taking effect the following day. The reverse split was approved by stockholders via written consent in December 2025.